

9 July 2026

Gastric and Gastro-oesophageal Junction (GOJ) Adenocarcinoma – Data Request (Last 12 Months)

1. How many patients have been diagnosed with locally advanced unresectable or metastatic gastric adenocarcinoma in your Trust in the last 12 months?

7 Patients

2. How many patients have been diagnosed with locally advanced unresectable or metastatic gastroesophageal junction (GOJ) adenocarcinoma in your Trust in the last 12 months?

11 Patients

3. Of the patients from Questions 1 and 2 (locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma), how many have been treated with each of the following regimens in your Trust?

a. Zolbetuximab + chemotherapy

None

b. Pembrolizumab + chemotherapy

<5 Patients

c. Nivolumab + chemotherapy

None

d. Paclitaxel + ramucirumab

None

e. Other chemotherapy (including but not limited to FLOT, FOLFOX, CAPOX, ECX, FOLFIRI)

<5 Patients (CAPOX)

<5 Patient TOX (Traztuzimab, Oxaliplatin, Capecitabine)

f. Best supportive care

9 Patients

9 July 2026

Some figures have been withheld and replaced with less than five (<5). This is because disclosure of small numbers has the potential to identify individuals. The information is therefore exempt under Section 40(2) of the Freedom of Information Act 2000 - Personal Information relating to a third party. Its release would contravene the data protection principles set out in the UK GDPR.